Oxidative Stress: a New Risk Factor for Thyroid Cancer

Mingzhao Xing

Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

(Commentary on the study of Wang et al, 2011)

Address correspondences and request for reprints to:

Michael Mingzhao Xing, M.D., Ph. D.
Professor of Medicine and Oncology
Division of Endocrinology and Metabolism
The Johns Hopkins University School of Medicine
Baltimore, MD 21287, USA
Email: mxing1@jhmi.edu
Abstract

Oxidative stress (OS) is a state of excessive free radicals and reactive metabolites among which the most important class is reactive oxygen species (ROS) — radicals derived from oxygen—as represented by the superoxide anion radical (O$_2^-$) and its reactive metabolites hydroxyl radical (HO$^\cdot$) and hydrogen peroxide (H$_2$O$_2$). In essence, OS represents an imbalance between the production of oxidants—ROS—and their elimination by antioxidative systems in the body. Many studies have linked OS to thyroid cancer by showing its association with abnormally regulated oxidative or antioxidative molecules. The study by Wang et al. in the December 2011 issue of *Endocrine-Related Cancer* (18 773–782) supports further this relationship by demonstrating a high total oxidant status and oxidative stress index in thyroid cancer patients. The origin of ROS in thyroid cancer patients has not been defined, but thyroid cancer itself can be one since inflammation, a major event in it, is a classical source of ROS. ROS may in turn enhance the MAP kinase and PI3K pathways, forming a malicious cycle propelling thyroid tumorigenesis. Regardless of the mechanism, the clinical implication of the association of OS with thyroid cancer is several-fold: one, OS is a new risk factor for thyroid cancer; two, OS confers thyroid cancer patients an increased risk for cardiovascular diseases, degenerative neurological disorders and other cancers that are classically associated with OS; and three, interference with OS may reduce this risk and be therapeutically beneficial to thyroid cancer itself in thyroid cancer patients. These interesting possibilities deserve further studies.
In recent years, many studies have linked oxidative stress (OS) to thyroid cancer (e.g., Senthil & Manoharan 2004, Akinci et al. 2008, Lassoued et al. 2010). These studies investigated the relationship of various individual oxidative or antioxidative molecules with thyroid cancer and provided evidence suggesting an association of OS with this cancer. In the study reported by Wang et al. in the December 2011 issue of Endocrine-Related Cancer, the authors took a further step to look at this issue and provided additional strong evidence to support an association of OS with thyroid cancer (Wang et al. 2011). A particularly important aspect of this study was the examination of also total oxidant status and oxidative stress index and demonstration of their strong association with thyroid cancer. These parameters likely fully reflect OS status in the body of a patient and thus could more accurately reflect the significance of OS in relation to thyroid cancer. Moreover, a unique strength of the Wang et al. study was also the inclusion of a group of patients with autoimmune thyroid diseases for comparison. Patients with autoimmune thyroid diseases have been shown to be associated with an increased OS (e.g., Andryskowski & Owczarek 2007, Erdamar et al. 2008, Torun et al. 2009, Aslan et al. 2011). Interestingly, the Wang et al. study found a much stronger association of OS with thyroid cancer in comparison with autoimmune thyroid diseases, consistent with previous similar studies on individual oxidative or antioxidative molecules (Lassoued et al. 2010), suggesting a more important role of OS in thyroid cancer. Although the mechanism for the link between OS and thyroid cancer and whether there is a causal relationship between the two have not been directly investigated, the report of Wang et al., together with the previous studies, seem to have now firmly established the association of the two.
The concept of OS has developed and evolved from the original free radical theory of oxygen toxicity nearly three scores of years ago (Gerschman et al. 1954, Commoner et al. 1954). OS represents a biochemical state of excessive presence of free radicals and reactive metabolites that exhibit harmful biological effects potentially damaging the organism (Valko et al. 2007, Durackova 2010). Free radicals are molecules or molecular fragments containing one or more unpaired electrons in atomic or molecular orbitals that confer the molecules considerable reactivity. Reactive oxygen species (ROS) — radicals derived from oxygen— are the most important class of radical species generated in organisms. Thus, OS represents an imbalance between the production of oxidants—ROS—and their elimination by the protective antioxidative systems in the body. A well-known basic radical ROS molecule is superoxide anion radical (O$_2^-$). Its metabolites, such as hydroxyl radical (HO•) and hydrogen peroxide (H$_2$O$_2$), are even more reactive. Another prominent radical system includes nitric oxide (NO•) and its metabolite peroxynitrite. ROS are products of normal cellular metabolisms. At low or moderate concentrations, they actually play an important beneficial role in certain physiological processes, such as cellular responses in defense against infectious agents and certain normal cellular signaling activities. Their excessive accumulation can cause damage of biological molecules and systems. The normal and important balance between beneficial and harmful effects of ROS in the body is maintained by redox regulation mechanisms that protect the body from OS (Dröge 2002). Not surprisingly, in humans OS has been well known to be associated with major diseases, such as diabetes mellitus, atherosclerosis, hypertension, inflammatory diseases, neurodegenerative disorders, and other diseases (Valko et al. 2007, Durackova 2010).
As with thyroid cancer, OS has also been known to be associated with other cancers (Lu et al. 2006; Valko et al. 2007, Durackova 2010). Although it is not clear mechanistically how OS can play a role in the pathogenesis of thyroid cancer, it seems that excessive ROS as a consequence of imbalanced intracellular redox systems may be an important event in the molecular pathogenesis of thyroid cancer, as implicated by cancers induced by certain chemicals, such as asbestos-induced lung cancer (Stayner et al. 1996) and iron-induced colorectal cancer (Valko et al. 2001). One potential consequence of this event may be DNA damage by ROS, resulting in mutagenic genetic alterations that can initiate carcinogenesis and development of cancer. Perhaps such genetic alterations could include those that can constitutively active major signaling pathways, such as the MAP kinase and PI3K/Akt pathways. In fact, previous studies have demonstrated that ROS, particularly H$_2$O$_2$, can activate the MAP kinase pathway signaling and consequent cellular proliferation (Rao & Berk 1992, Guyton et al. 1996, Aikawa et al. 1997). There are also studies showing that the PI3K/Akt and NFκB pathways can be activated by ROS (Poli et al. 2004, Spencer 2005, Durackova 2010). These studies thus demonstrate a direct role of ROS in affecting the major intracellular signaling pathways that are widely involved in human tumorigenesis.

Over activation of the MAP kinase and PI3K/Akt pathways is a fundamental mechanism in the tumorigenesis of thyroid cancer (Xing 2007, Xing 2010). NFκB pathway also plays a role in thyroid tumorigenesis (Liu & Xing 2008, Pacifico et al. 2010). It is thus plausible to propose that ROS may play a role in the pathogenesis of thyroid cancer through affecting these signaling pathways. Consequently, this may represent a mechanistic link of OS with thyroid cancer and make ROS a novel contributing factor to the pathogenesis of thyroid cancer— an interesting
hypothesis that is tempting to test. As genetic alterations of the MAP kinase and PI3K/Akt pathways, such as the mutations in the *BRAF*, *Ras*, *PIK3CA*, and *PTEN* genes, are a dominant driving force for the activation of these pathways (Xing 2007, Xing 2010), it would be interesting to see how ROS could interact or cooperate with these genetic alterations in promoting the pathogenesis and progression of thyroid cancer. Perhaps a similar clinical approach as used in the Wang *et al.* study could be employed to see how OS levels might be specifically linked to the aggressiveness of thyroid cancer with respect to various genetic backgrounds.

ROS can stimulate the production of matrix metalloproteinase and various cytokines such as transforming growth factor (TGF)β1 (Poli *et al.* 2004, Valko *et al.* 2007, Durackova 2010). This may potentially be another mechanism for the role of ROS in the pathogenesis of thyroid cancer. Recent studies have established that alterations in extracellular matrix microenvironments involving abnormal production of matrix metalloproteinases and inflammatory cytokines are a major molecular mechanism in BRAF mutant-promoted pathogenesis and progression of thyroid cancer (Nucera *et al.* 2011). In this process, cytokine TGFβ1 has been shown to play a particularly important role (Riesco-Eizaguirre *et al.* 2009, Knauf *et al.* 2011). Interestingly, expression of TGFβ1 is not only increased under the state of increased OS, ROS can also be down-stream intermediates of TGFβ1 (Poli *et al.* 2004). On the other hand, one study showed that under *in vitro* conditions certain ROS-enhancing agents could somehow paradoxically induce degradation of the BRAF mutant (Fukuyo *et al.* 2008). Thus, BRAF mutant, TGFβ1, and ROS may have a complex relationship and role in the pathogenesis of thyroid cancer.
If the mechanism in the link of OS with thyroid cancer involves an active role of ROS in promoting the pathogenesis of thyroid cancer as discussed above, there needs to be a source that persistently supplies ROS in the condition of thyroid cancer. In other words, a fundamental question is how excessive ROS is produced in patients with thyroid cancer. One answer may lie in the fact that thyroid cancer, like many other cancers (Lu et al. 2006), is, in many ways, an inflammatory disease. It has become well known in recent years that thyroid cancer is often abundantly infiltrated with inflammatory cells and various important inflammatory cytokines are actively produced in thyroid cancer (Nucera et al. 2011). Some of these inflammatory cytokines have an established important role in thyroid tumorigenesis, such as TGFβ1 as discussed above (Riesco-Eizaguirre et al. 2009, Knauf et al. 2011) and thrombospondin-1 (Nucera et al. 2010). Thus, inflammatory process in thyroid cancer and the ensuing development of inflammatory microenvironments seem to be an integral part of the pathogenesis of thyroid cancer. BRAF mutation, which is the most common activating mutation in thyroid cancer and is associated with tumor progression and aggressiveness (Xing et al. 2005), could elicit strong inflammatory responses of this cancer (Nucera et al. 2011). This inflammatory environment of thyroid cancer is conceivably a significant source of ROS since inflammation is a well-established classical condition that produces high OS (Poli et al. 2004, Lu et al. 2006). It is also possible that the common oncogenic mutants in thyroid cancer, such as the BRAF mutant, could increase the production of ROS through a yet-to-be-defined non-inflammatory mechanism. An interesting mechanism could thus be that oncogene-promoted production of ROS in turn promotes the pathogenesis and progression of thyroid cancer by enhancing the activation of major signaling pathways initiated by oncogenes, forming a malicious cycle that propels the pathogenesis of thyroid cancer.
There may be other mechanisms by which ROS can be produced in thyroid cancer causing a high OS state. In fact, the thyroid gland itself is a site where reactive radical molecule species are actively generated through the process of iodide metabolism and thyroid hormone synthesis. In this process, signaling of thyroid-stimulating hormone (TSH) acting on the TSH receptor (TSHR) on thyroid cells stimulates the synthesis of H$_2$O$_2$, which is the substrate of thyroperoxidase in thyroglobulin iodination and thyroid hormone synthesis (Corvilain et al. 1991). ROS is therefore generated actively in the process of TSH stimulation of thyroid cells. Differentiated thyroid cancer cells usually express functional TSHR. It is thus conceivable that such thyroid cancer cells, upon stimulation by TSH secreted by the pituitary gland, could actively produce H$_2$O$_2$, thus contributing to the high OS state in thyroid cancer patients.

Interestingly, several studies in recent years have demonstrated a strong association of high TSH levels with an increased malignancy risk of thyroid nodules (Boelaert et al. 2006, Haymart et al. 2009). The mechanism of this association has been unclear. Now given the link of OS with thyroid cancer and the possible mechanism involving ROS in promoting thyroid tumorigenesis discussed above, stimulation of H$_2$O$_2$ production by TSH acting on TSHR may represent one explanation. Such a mechanism is well consistent with the previous demonstrations that ROS can activate the thyroid cancer-promoting MAP kinase, PI3K/Akt, and NFκB pathways as discussed above.

Whether other OS-generating conditions tend to exist in patients with thyroid cancer other than the source of thyroid cancer itself remains to be investigated. Regardless of the source, the high
OS state in thyroid cancer patients may also have important non-thyroid-cancer health implications in these patients. For example, since OS is associated with cardiovascular disease, diabetes mellitus, neurodegenerative disorders, and other cancers, it remains an important question whether thyroid cancer patients are predisposed to these diseases and may therefore warrant appropriate surveillance and special prevention for such diseases. Further biological and epidemiological studies are needed to address this important issue. Whether interference in the metabolism of ROS to reduce OS by targeting the potential mechanisms discussed above or by taking antioxidative measures can be preventative and therapeutic for such diseases in thyroid cancer patients and for thyroid cancer itself remains to be an interesting question to answer.

Regardless of the source of high OS in thyroid cancer, the strong association of OS with thyroid cancer demonstrated by Wang et al. (2011) and other investigators in recent years and the plausible molecular mechanisms discussed above strongly suggest that high OS is a risk factor associated with thyroid tumorigenesis and likely a risk factor for the progression of thyroid cancer as well. There are very few known thyroid cancer risk factors, among which the best established are radiation exposure and family history of thyroid cancer, which are currently clinically used in the risk assessment of thyroid nodules (Cooper et al. 2009). Although most of the mechanistic aspects or hypotheses discussed above regarding the role of OS in thyroid cancer remain to be directly tested, it seems to be convincing that high OS represents a new risk factor for thyroid cancer. It is thus tempting to propose that testing of OS, particularly in the form of total oxidant status and oxidative stress index as proposed by Wang et al (2011), may be clinically useful in the risk assessment of thyroid nodules.
Acknowledgements: Supported by the National Institutes of Health R0-1 grant R01CA134225 to MX.

References


Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. *Oncogene* **30** 3153-3162.


Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M & Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor beta
secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. *Cancer Research* **69** 8317-8325.


Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E & Tutuncu NB 2009 Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. *Clinical Endocrinology (Oxf)* **70** 469-474.


